Search Results

• • 33 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Has SARS-CoV-2 reached peak fitness?

  Authors:Roberto Burioni and Eric J. TopolFrom:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 20211,127 words Letter to the editor 1520LAuthor(s): Roberto Burioni 1 , Eric J. Topol 2 Author Affiliations: (1) Università Vita-Salute San Raffaele, Milano, Italy (2) The Scripps Research Institute, La Jolla, USA To the Editor --For the first time in...

• Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.

  Authors:Tien Dam, Adam L. Boxer, Lawrence I. Golbe, Günter U. Höglinger, Huw R. Morris, Irene Litvan, et al.From:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 20219,546 words Report 1680LA randomized, double-blind, placebo-controlled, 52-week study (no. NCT03068468) evaluated gosuranemab, an anti-tau monoclonal antibody, in the treatment of progressive supranuclear palsy (PSP). In total, 486 participants...

• Retrieval of vector integration sites from cell-free DNA.

  Authors:Daniela Cesana, Andrea Calabria, Laura Rudilosso, Pierangela Gallina, Fabrizio Benedicenti, Giulio Spinozzi, et al.From:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 202117,423 words Report 1700LGene therapy (GT) has rapidly attracted renewed interest as a treatment for otherwise incurable diseases, with several GT products already on the market and many more entering clinical testing for selected indications....

• Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality.

  Authors:Benjamin J. Cowling, Wey Wen Lim, and Sarah CobeyFrom:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 20211,486 words Letter to the editor 1640LAuthor(s): Benjamin J. Cowling 1 2 , Wey Wen Lim 1 , Sarah Cobey 3 Author Affiliations: (1) World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li...

• Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial.

  Authors:Charlotte K. Boughton, Afroditi Tripyla, Sara Hartnell, Aideen Daly, David Herzig, Malgorzata E. Wilinska, et al.From:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 20216,339 words Report 1520LWe evaluated the safety and efficacy of fully closed-loop insulin therapy compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis. In an open-label, multinational, two-center, randomized...

• Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom.

  Authors:Emma Pritchard, Philippa C. Matthews, Nicole Stoesser, David W. Eyre, Owen Gethings, Karina-Doris Vihta, et al.From:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 20218,921 words Report 1710LThe effectiveness of COVID-19 vaccination in preventing new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the general community is still unclear. Here, we used the Office for National...

• Integrated genomic, epidemiologic investigation of Candida auris skin colonization in a skilled nursing facility.

  Authors:Diana M. Proctor, Thelma Dangana, D. Joseph Sexton, Christine Fukuda, Rachel D. Yelin, Mary Stanley, et al.From:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 202110,924 words Report 1590LCandida auris is a fungal pathogen of high concern due to its ability to cause healthcare-associated infections and outbreaks, its resistance to antimicrobials and disinfectants and its persistence on human skin and in...

• A novel treatment for heart failure targets myocardial fibrosis.

  Authors:John G. F. Cleland, Pierpaolo Pellicori, and Arantxa GonzálezFrom:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 20211,565 words Article 1500LA new trial suggests that pirfenidone, an approved treatment for idiopathic pulmonary fibrosis, may also reduce myocardial fibrosis in patients with heart failure who have a preserved left ventricular ejection fraction....

• Publisher Correction: A systems approach identifies HIPK2 as a key regulator of kidney fibrosis.

  Authors:Yuanmeng Jin, Krishna Ratnam, Peter Y. Chuang, Ying Fan, Yifei Zhong, Yan Dai, et al.From:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 2021220 words Disease/Disorder ove... 2090LAuthor(s): Yuanmeng Jin 1 2, Krishna Ratnam 1, Peter Y. Chuang 1, Ying Fan 1, Yifei Zhong 1, Yan Dai 1, Amin R. Mazloom 3 4, Edward Y. Chen 3 4, Vivette D'Agati 5, Huabao Xiong 6, Michael J. Ross 1, Nan Chen 2, Avi...

• Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection.

  Authors:Henrik Salje, Maria Theresa Alera, Mary Noreen Chua, Taweewun Hunsawong, Damon Ellison, Anon Srikiatkhachorn, et al.From:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 20218,112 words Report 1510LMore than half of the world's population lives in areas at risk for dengue virus infection. A vaccine will be pivotal to controlling spread, however, the only licensed vaccine, Dengvaxia, has been shown to increase the...

• Understanding COVID-19 vaccine hesitancy.

  Authors:Shingai Machingaidze and Charles Shey WiysongeFrom:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 20211,283 words Article 1580LA new study unpacks the complexities of COVID-19 vaccine hesitancy and acceptance across low-, middle- and high-income countries. Author(s): Shingai Machingaidze 1 2 , Charles Shey Wiysonge 2 3 Author Affiliations:...

• Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.

  Authors:Miles C. Andrews, Connie P. M. Duong, Vancheswaran Gopalakrishnan, Valerio Iebba, Wei-Shen Chen, Lisa Derosa, et al.From:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 202115,811 words Report 1600LTreatment with combined immune checkpoint blockade (CICB) targeting CTLA-4 and PD-1 is associated with clinical benefit across tumor types, but also a high rate of immune-related adverse events. Insights into biomarkers...

• CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.

  Authors:Jay Y. Spiegel, Shabnum Patel, Lori Muffly, Nasheed M. Hossain, Jean Oak, John H. Baird, et al.From:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 202113,542 words Report 1570LDespite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with large B cell lymphoma (LBCL) with...

• AI in medicine must be explainable.

  Author:Shinjini KunduFrom:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 2021962 words Article 1190LAI algorithms used for diagnosis and prognosis must be explainable and must not rely on a black box. Author(s): Shinjini Kundu 1 Author Affiliations: (1) The Johns Hopkins Hospital, Baltimore, USA In the wake of...

• Tumor-infiltrating lymphocytes make inroads in non-small-cell lung cancer.

  Authors:Joshua R. Veatch, Sylvain Simon, and Stanley R. RiddellFrom:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 20211,389 words Article 1670LA phase 1 trial shows promising anti-tumor activity of tumor-infiltrating-lymphocyte therapy in patients with advanced non-small-cell lung cancer. Author(s): Joshua R. Veatch 1 2 , Sylvain Simon 1 , Stanley R. Riddell...

• Record number of gene-therapy trials, despite setbacks.

  Author:Carrie ArnoldFrom:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 20212,851 words Article 1250LThe recent failure of a gene therapy for Huntington's disease was devastating for patients, but researchers remain optimistic. Author(s): Carrie Arnold 1 Author Affiliations: (1) Science writer, Richmond, USA For...

• Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.

  Authors:Benjamin C. Creelan, Chao Wang, Jamie K. Teer, Eric M. Toloza, Jiqiang Yao, Sungjune Kim, et al.From:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 202113,680 words Report 1430LAdoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer. We conducted a single-arm open-label phase...

• Giving voice to Black women in science and medicine.

  Authors:Eseosa T. Ighodaro, Erica L. Littlejohn, Adesuwa I. Akhetuamhen, and Richard BensonFrom:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 20211,139 words Letter to the editor 1490LAuthor(s): Eseosa T. Ighodaro 1 , Erica L. Littlejohn 2 , Adesuwa I. Akhetuamhen 3 , Richard Benson 2 Author Affiliations: (1) Department of Neurology, Mayo Clinic, Rochester, USA (2) Office of Global Health and...

• Remove obstacles to sharing health data with researchers outside of the European Union.

  Authors:Heidi Beate Bentzen, Rosa Castro, Robin Fears, George Griffin, Volker ter Meulen, and Giske UrsinFrom:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 20213,646 words Article 1650LCOVID-19 has shown that international collaborations and global data sharing are essential for health research, but legal obstacles are preventing data sharing for non-pandemic-related research among public researchers...

• Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals.

  Authors:Oren Milman, Idan Yelin, Noga Aharony, Rachel Katz, Esma Herzel, Amir Ben-Tov, et al.From:Nature Medicine (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 20213,904 words Report 1590LMass vaccination has the potential to curb the current COVID-19 pandemic by protecting individuals who have been vaccinated against the disease and possibly lowering the likelihood of transmission to individuals who have...